Newsroom
Category
October 6, 2017
SAN ANTONIO (Oct. 6, 2017) ― Top researchers from around the country will join mental health professionals and others interested in improving care for the psychological wounds of war at the Second Annual San Antonio Combat PTSD Conference on Oct. 18-19. Presented by the STRONG STAR Consortium and Consortium to Alleviate PTSD (CAP), two federally […]
October 5, 2017
William L. Henrich, M.D., MACP, president of UT Health San Antonio, recognized the John L. Santikos Charitable Foundation, a fund of the San Antonio Area Foundation, on Oct. 2 for its $2.3 million gift to build the John L. Santikos CT and Nuclear Medicine Suite at the university. The state-of-the-art imaging suite is on the […]
October 3, 2017
Anti-cancer drugs called mTOR inhibitors slow the growth of cancer cells but show limited ability to cause cancer cell death. New studies explain why. Masahiro Morita, Ph.D., assistant professor of molecular medicine in the Joe R. & Teresa Lozano Long School of Medicine at UT Health San Antonio, contributed to the research. He is a […]
October 2, 2017
WHAT: Drug Dealer, MD: How Doctors Were Duped, Patients Got Hooked, and Why It’s So Hard to Stop WHEN: 5:30 to 7 p.m. Thursday, Oct 5 WHERE: UT Health San Antonio Pestana Lecture Hall, 7703 Floyd Curl Drive, San Antonio, Texas 78229 WHO: Anna Lembke, M.D. NOTE: Free and open to […]
October 2, 2017
Time-release formulation designed for children with severe ADHD symptoms upon awakening SAN ANTONIO (Oct. 2, 2017) ― UT Health San Antonio psychiatrist Steven Pliszka, M.D., is lead author on a study that shows a new formulation of an established medication for attention deficit hyperactivity disorder (ADHD) significantly improves severe morning symptoms. Dr. Pliszka is the Dielmann Distinguished […]
September 28, 2017
Researchers from the Greehey Children’s Cancer Research Institute at UT Health San Antonio are co-authors on a paper published Sept. 26 in Science Signaling, a high-impact journal that is part of the Science family of journals. RAS mutations are implicated in several cancers, including lung, colorectal and pancreatic ductal carcinoma. The three RAS genes are […]
